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Cell-free nucleic acids (CFNA) have been reported by several authors in blood, stool,
and urine of patients with colorectal cancer (CRC). These genetic biomarkers can be
an indication of neoplastic colorectal epithelial cells, and can thus potentially be used
as noninvasive tests for the detection of the disease in CRC patients and monitor their
staging, without the need to use heavier and invasive tools. In a number of test-trials,
these genetic tests have shown the advantage of non-invasiveness, making them well
accepted by most of the patients, without major side effects. They have also shown
a promising sensitivity and specificity in the detection of malignant and premalignant
neoplasms. Moreover, costs for performing such tests are very low. Several studies
reported and confirmed the proof of the principle for these genetic tests for screening,
diagnosis, and prognosis; the main challenge of translating this approach from research to
clinical laboratory is the validation from large and long-term randomized trials to prove
sustainable high sensitivity and specificity. In this paper, we present a review on the
noninvasive genetics biomarkers for CRC detection described in the literature and the
challenges that can be encountered for validation processes.
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INTRODUCTION
Colorectal cancer (CRC) is the most common cancer world-
wide, and it is the second cause of cancer death just behind lung
cancer (Ferlay et al., 2010). Recent data collected by Globocan,
show an estimated 1.3 million new CRC cases during 2012,
693,881 resulting in death (http://globocan.iarc.fr/Pages/online.
aspx). The CRC incidence and mortality are actually increasing
despite recent advances in surgery, radiotherapy and chemother-
apy (Boyle and Langman, 2000). Tumor progression of CRC is
governed by either genetic or epigenetic changes intrinsic to neo-
plastic colorectal epithelial cells. CRC can be caused by changes in
different molecular pathogenic pathways, such as chromosomal
instability, CpG island methylator phenotype, and microsatellite
instability. The majority of the cases are sporadic (not inher-
ited). Sporadic changes may be acquired from diverse factors such
as environmental exposures, diet, hormones, and normal aging.
There are also cases of inherited CRC, the most known hereditary
CRC being Familial adenomatous polyposis (FAP), Hereditary
nonpolyposis colorectal cancer (HNPCC), Autosomal recessive
adenomatous polyposis, and Oligodontia-colorectal cancer syn-
drome (Haggar and Boushey, 2009; Schweiger et al., 2013).
Mutations in a single gene such as APC, MSH2, MLH1, PMS1,
PMS2, MSH6, TGFBR2, MLH3, MUTYH, and AXIN2 result in a
marked predisposition to mentioned hereditary CRC (Schweiger
et al., 2013).
In most cases, the natural history of CRC follows a progres-
sion from benign polyps to advanced CRC, this process often
spanning several years. Tumor detection at early disease stages
together with monitoring of disease progression toward malig-
nancy, have shown a reduction in mortality rates (Scholefield
et al., 2012; Shaukat et al., 2013). Thereby, tumor control leads
to better care of affected patients. Colonoscopy is currently the
standard approach to tumor diagnosis, with a relatively high cost
and recognized invasiveness with the potential for serious com-
plications. Practical limitations restrict the use of colonoscopy
for screening. An alternative method, Fecal Occult Blood Testing
(FOBT) has been widely used to detect blood in fecal samples. The
FOBT employs the pseudoperoxidase activity of hemoglobin’s
heme moiety in blood containing samples. More recently, the use
of an immunological reaction directed to detect hemoglobin via
heme-specific antibody has served as an alternative to the enzyme
detection method. Unfortunately, several trials have shown the
occurrence of a high rate of false-negatives and positives for these
tests (Imperiale et al., 2004; Ebert et al., 2006; Bin Raies et al.,
2013; Mansour et al., 2013; Roperch et al., 2013), Therefore, the
need to develop an effective noninvasive assay to screen patients
for CRC at early stages remains urgent.
CFNA MARKERS IN BODY FLUIDS
OUTLOOK
Since the first discovery in 1948 by Mandel of the occurrence
of CFNA in blood (Mandel and Metais, 1948), researchers have
found nucleic acids in body fluids that track and discrimi-
nate affected patients from healthy subjects. In the cancer field,
researchers have also found traces of shed tumoral-nucleic acids
in different biological effluents such as stool, blood, and urine.
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The recognition of the advantages and the proof-of-concept of
using CFNAs for noninvasive cancer detection naturally followed
their discovery (Imperiale et al., 2004; Muller et al., 2004; Ebert
et al., 2006; Mansour and Sobhani, 2009; Roperch et al., 2013).
SELECTION OF LITERATURE
We performed a literature search to capture identified tumor-
related CFNAs reported to distinguish CRC patients from healthy
subjects. Thereby, a search from the NCBI Entrez search line
selected to the PubMed index was performed with the follow-
ing string: (plasma OR serum OR stool OR urine OR blood OR
body fluids) AND (colorectal cancer OR colorectal neoplasms
OR colorectal neoplasm OR colon cancer OR rectal cancer) AND
(mutation ormethylation ormicroRNAOR transcript ORmRNA
ORmiR OR RNA). The search yielded 3674 entries. The addition
of the term “noninvasive” to the search string reduced the num-
ber of resulting titles to 109. The output data identified by these
later inclusion criteria are reviewed and summarized in Table 1.
LITERATURE SEARCH RESULTS
This section is organized as follows: We first describe the differ-
ent available molecular approaches for the detection of anomalies
in CFNA in body fluids, we then review the inclusion criteria
for the patient cohorts and we finally describe the known CFNA
biomarkers.
Molecular approaches
Several molecular approaches are used to detect the CFNA in
the body fluids of CRC patients and to quantify the molecu-
lar anomalies that could reveal neoplastic traces. The quanti-
tative polymerase chain reaction (QPCR or RT-PCR) is widely
used. Other tools are also reported such as DNA Beaming
Technology, Methylation Array, DNA array, Surface-Enhanced
Raman Scattering (SERS), and Restriction Fragment Length
Polymorphism (RFLP). While most of these methods capture
and enrich the tumoral nucleic acids to bring their levels to the
detection and quantification thresholds, the sensitivity of these
instruments, and techniques vary considerably with a resulting
influence on the performance of the test to distinguish the can-
cer from the normal. This variability was observed even when
evaluating the same marker. One new molecular approach for
evaluation the whole CFNA that can be found in the body flu-
ids is the use of next generation sequencing (NGS), as in Leary
et al. (2012). They scanned the whole genome of plasmatic DNA
to detect which composites of chromosomal structure varia-
tions present in CRC tumorigenesis could discriminate between
CRC patients and healthy subjects. Promising results were found
discriminating CRC patients at advanced stage from healthy con-
trols, but these results would benefit from a more in-depth study
on a large cohort and at earlier disease stages. This study did
emphasize the value of using NGS to CRC detection. NGS applied
to CRC detection could provide high sensitivity through high
sequencing coverage and selectivity through complete analysis of
high quality data.
Patients
In term of patients’ inclusion and tumor criteria, the majority
of these studies used average-risk population. Different tumor
sizes were considered: small adenomas, adenomas having more
than 1 cm in size and carcinomas at different stages (I, II, III,
or IV). The cancer locations were mainly ascending colon, trans-
verse colon, descending colon, sigmoid colon, and rectum. Three
clinical trials differed strongly from all the others. The first one
was a study from Manenti et al. (Villa et al., 1996), focusing on
Kras gene mutations in the stool of 230 consecutive patients.
The consecutive patient selection strategy gives unbiased sensi-
tivity and specificity regarding the test used and clearly aims to
avoid bias possibly introduced by patient selection. The two oth-
ers outstanding studies were performed by Imperiale et al. They
evaluated 21 mutations in APC, Kras, and P53 genes on asymp-
tomatic subjects (n = 4404) tested already for FOBT (Imperiale
et al., 2004), and they recently evaluated KRAS mutations, aber-
rant NDRG4 and BMP3 methylation, and β-actin on very large
number of individuals (n = 9989) tested for FIT (Imperiale et al.,
2014). Inclusion of a very large number of asymptomatic sub-
jects shows the potential of sensitivity gain for molecular testing
(Imperiale et al., 2004, 2014). With these inclusion criteria, the
authors simulated a real situation of screening and applied pow-
erful statistical tools to evaluate the true performance of the
test used. Globally, the authors claim a higher sensitivity for the
multitarget stool DNA testing over the two tests FOBT and the
FIT, but had more false positives results (Imperiale et al., 2004,
2014). Other authors have identified, albeit in small cohorts, sev-
eral others combinations of useful biomarkers. Studies directed
at larger cohorts are awaited to provide confidence on the per-
formance of the composite panels that were chosen for these
studies.
Biomarkers
The first results to provide a conceptual framework and a practi-
cal basis for a new molecular approach to detect the presence of
genetic anomalies in CFNAs isolated fromCRC patient stool sam-
ples were published in 1992 by Bert Vogelstein et al. (Sidransky
et al., 1992). In this work, the authors were able in a rela-
tively easy manner, to detect K-ras gene mutations in patients
with CRC. They successfully detected Kras mutation in 89%
of the patients. Since this first published results targeting Kras,
other anomalies were measured directly from CFNAs includ-
ing deletions, microsatellite instability, loss of heterozygosity,
copy number variation, chromosomal rearrangements, DNA, and
microRNA methylation changes and mis-expression of mRNAs
and microRNAs. Many genes have been shown affected in CRC,
are involved in various critical signaling molecular pathways,
but their diagnostic usefulness and specificity vary considerably.
Here follows a description of the most common CFNA biomark-
ers, subdivided by subclasses, namely mutation, methylation, and
microRNA.
MUTATION BIOMARKERS
KRAS
Kras, a Kirsten ras oncogene, encodes a protein that is a member
of the small GTPase superfamily. The protein is involved in many
vital signaling pathways, including proliferation, differentiation,
and senescence. A single amino acid substitution is responsible
for an activating mutation. The transforming protein that results
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Table 1 | Summary of genetic markers found in body fluids from CRC patients.
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
Mutation
(codons 12 or 13)
K-ras Stool 66.70% 100% Hybridization assays and
Southern-blot
Sidransky et al., 1992
Expression PKC isoforms Feces ND ND Immunoblotting and
mRNA directed PCR
Davidson et al., 1994
Mutation (codon
12 or 13)
K-ras Stool 18.10% ND MASA-PCR method and
gel blotting
Hasegawa et al.,
1995
Mutation (Asp13,
Val12, Asp12)
K-ras Stool 29.90% 95.7% PCR and Oligomer-specific
hybridization
Villa et al., 1996
Mutation (codon
12 or 13)
K-ras Stool 40% 100% PCR and Restriction
enzyme analysis
Ratto et al., 1996
Expression
(variant 6 and 10)
Cd44 Stool 60–68% ND RT-PCR followed by
Southern-blot
Yamao et al., 1998
Mutation (exon
4, 5, 6, 7 and 8)
P53 Blood 0% dukes stage A, 11%
B, 18% C,
ND Antibody Ber EP4
selection, RT-PCR and
sequencing
Khan et al., 2000
Mutation (exons
5–8)
P53 Stool 0% dukes’ stage A, 5%
B, 5% C, and 33% D
100% PCR followed by
denaturing gradient gel
electrophoresis and
sequencing
Rengucci et al., 2001
Mutation (exons
1–2)
Kras 0% dukes’ stage A, 10%
B, 20% C, and 0% D
100%
Microsatellites
instability
D2S123,
D5S346,
D17S250,
BAT25, BAT26
0 % dukes’ stage A, 5%
B, 5% C, and 33% D
100%
9 mutations TP53 Stool 71% (dukes’ A 100%, B
82%, C 67%, and D
58%)
ND Mismatch-ligation assay,
modified solid-phase
mini-sequencing method
and Digital PCR-based
method
Dong et al., 2001
Deletion Bat26
Mutations
(codons 12–13)
Kras
Mutation
(GAT/TGT/
GTT/AGT/GAC)
Kras Stool 100% (6/6 found in
tissue)
100% Enrichment by biotinylated
primers and streptavidin
beads followed by
Single-Strand
Conformational
Polymorphism
Doolittle et al., 2001
27 Mutations
(codons 1210
and 1581)
APC Stool 57% neoplasia (17/28
dukes’B2 and 9/18
adenomas)
100% Digital protein truncation
(in vitro transcription and
translation of
amplified-DNA)
Traverso et al., 2002
Microsatellites
instability and
lost of
heterozygosity
P53 Stool P53: sporadic cancer:
86.7% (26/30) and
HNPCC 36.3% (4/11),
86.70% PCR and fragment analysis Koshiji et al., 2002
APC APC: sporadic cancer:
76.6% (23/30) and
HNPCC 54.5% (6/11),
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
D9S162 D9S162: sporadic cancer:
73.3% (22/30) and
HNPCC 54.5% (6/11).
P53 and APC: 96.7%
(sporadic cancer)
P53, APC, and D9S162:
100% (sporadic cancer)
D9S171 Sporadic cancer: 36.6%
(11/30) and HNPCC
36.3% (4/11)
ND
hMLH1 sporadic: 70% (21/30)
and HNPCC 100% (11/11)
ND
IFNA sporadic: 66.6% (20/30)
and HNPCC 72.7% (8/11)
ND
DCC sporadic: 53.3% (16/30)
and HNPCC 81.8% (9/11)
ND
Mutation in the
first or second
position of
codon 12
Kras Sera 31% (5/16) of carcinoma
and 50% (2/4) ulcerative
pancolitis, 0%
adenomas, 0% Crohn
disease
100% RFLP-PCR Borchers et al., 2002
Microsatellite
instability
(Deletion)
BAT-26 Stool 83% of successfully
amplified samples. P53
(42%), Apc (37%), K-ras
(28%), and BAT-26 (24%)
ND PCR Berger et al., 2003
Mutation (in 19
loci)
P53, K-ras, Apc
Mutation in
exons 5-8
P53 Stool ND ND Calistri et al., 2003
Microsatellite
instability (5 loci)
ND 6%
Mutation in
exons 1-2
Kras 11%
Mutation (4
fragments in
exon 15)
APC 2%
Expression of
telomersae
hTERT Plasma 98% 64% qRT-PCR Lledo et al., 2004
Methylation SFRP2 Stool QPCR Muller et al., 2004
CpG island
Methylation
ESR1 Stool ND ND Methylation-specific PCR
and Cobra assay
Belshaw et al., 2004
MGMT ND ND
HPP1 ND ND
p16(INK4a) ND ND
APC ND ND
MLH1 ND ND
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
Muattion (21
mutations)
Kras, APC and
P53
Stool 51.6 % (16/31) invasive
cancers, 40.8% (29/71)
invasive cancers plus
adenomas with
high-grade dysplasia and
18.2% (76/418) advanced
neoplasia
94% Oligonucleotide-based
hybrid captures in DNA
extraction followed by
Specific PCR and capillary
sequencing or Real Time
PCR
Imperiale et al., 2004
Microsatellite
instability
BAT-26
DNA
degradation
marker
long DNA
Methylation APC Serum 57 % (28/49) with at
least one marker
95 % Quantitative
methylation-specific PCR
(MethyLight PCR)
Leung et al., 2005
hMLH1
HLTF
Mutation (22
mutations)
Kras, APC, P53,
bat-26
Stool 72% ND DNA analyzed gel-based
capture
Itzkowitz et al., 2007
DNA integrity
assay (DIA)
Long DNA ND
Methylation Vimentin 72.50% 86.90%
Mutation in
codon 12
Kras Stool 41% (12/29) 95% Nested RT-PCR and
amplified restriction
fragment length
polymorphism analysis
Chien et al., 2007
Mutation in
codon 12
Kras Stool 54% (14/26) ND Restriction
endonuclease-mediated
selective (REMS)-PCR
Mixich et al., 2007
Methylation SFRP2 Stool 94.2% cancer, 52.4%
adenoma, 28.5%
H. polyps and U. colitis
95.80% MSP Huang et al., 2007.
DNA integrity Long DNA Stool 64% 95.00% PCR, denaturating
polyacrylamide gel, and
MSP
Abbaszadegan et al.,
2007
Methylation P16 20% 100.00%
Microsatellite
instability
Bat-26 0% 100.00%
Methylation SFRP2 Stool 89% 86.00% Methylation-specific
polymerase chain reaction
Zhang et al., 2007
Methylation SFRP2 Stool 87.0% (60/69) CRC,
61.8% (21/34) adenoma
and 42.3% H. polyp
(11/26)
93.00% MethyLight PCR Wang and Tang,
2008
Methylation TFPI2 Stool 76–89% 79–93% Quantitative
methylation-specific PCR
Glockner et al., 2009
Methylation GATA4 Stool 71% (in the training set)
and 51% in the
(validation set)
84% in the
1st set and
93% in the
2d set
Quantitative MSP Hellebrekers et al.,
2009
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
Methylation NDRG4 Stool 61% (training set) and
53% (test set)
93%
(training set)
and 100%
(test set)
Quantitative MSP Melotte et al., 2009
Methylation MGMT Stool 75.0% for CRC and
59.6% for adenoma
86.50% MSP Baek et al., 2009
hMLH1
Vimentin
Methylation RASSF2 Stool 75.0% colorectal cancer
and 44.4% advanced
colorectal adenomas
89.40% Single-step modification of
DNA with sodium bisulfite
and fluorescence
polymerase chain reaction
methodology
Nagasaka et al.,
2009
SFRP2
Methylation RARB2 Stool In the initial set:75% of
carcinomas, 60% of
adenomas; in replication
set: 62% of carcinomas
et 40% of adenomas
100.00% Methylation-specific
melting curve analysis
(MS-MCA)
Azuara et al., 2010
p16INK4a
MGMT
APC
Methylation ALX4 Plasma 81% 90.00% MethyLight PCR He et al., 2010
Sept9
TMEFF2
Mutation Kras Stool 56.60% 93.30% Chip-based temperature
gradient capillary
electrophoresis (TGCE)
Zhang et al., 2011a
Methylation Mal Stool 92.8% colorectal cancer,
70.8% in colon
adenomas
96.20% Methylation-specific
PCR(MSP)
Kang et al., 2011
CDKN2A 100.00%
MGMT 96.20%
Methylation TFPI2 Stool 86.70% 83.30% Methylation-specific PCR
(MSP)
Zhang et al., 2012
DNA integrity Long DNA
Methylation Vimentin Stool 86.7% CRC and 76.5%
for adenoma
86.70% Methylation-specific
polymerase chain reaction
(MSP)
Zhang et al., 2011b
OSMR
TFPI2
Mutation (3925
G > A, 4012 C >
T, 4067 C > T,
and 4099 C > T)
APC Stool 50% ND Hydrogel bead-array Deng et al., 2012
Mutation (814 G
> A and 818
G > A)
TP53
Mutation (35
G > T and 38
G > A)
Kras
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
SERS spectra RNA Serum 89.10% 95.60% Surface-enhanced Raman
scattering (SERS), platform
Chen et al., 2012
Chromosomal
alterations
Whole genome Plasma 100% 100% NGS Leary et al., 2012
Methylation Spastic
paraplegia-20
Stool 80.20% 100% Methylation specific PCR Zhang et al., 2013a
Methylation AGTR1 Stool 78.00% ND Methylation array and
pyrosequencing
Carmona et al., 2013
WNT2
SLIT2
Methylation FBN1 Stool 72.00% 93% Methylation-specific PCR Guo et al., 2013
Mutation APC Stool ND ND Wild-type blocking PCR
and high-resolution melting
(WT-HRM)
Gerecke et al., 2013
Mutation and
Methylation
KRAS mutations,
aberrant NDRG4
and BMP3
methylation, and
β-actin
Stool 92.3% colorectal cancer,
42.4% advanced
precancerous lesions,
69.2% polyps with
high-grade dysplasia,
42.4% serrated sessile
polyps measuring 1 cm
or more
86% Quantitative Molecular
Assays
Imperiale et al., 2014
MicroRNA
expression
miR-532-3p Plasma Polyps discrimination
from controls with high
accuracy
ND Microfluidic array
technology
Kanaan et al., 2013
miR-331
miR-195
miR-17
miR-142-3p
miR-15b
miR-532
miR-652
miR-29a Plasma 83% 85% RT-PCR Huang et al., 2010
miR-92a Plasma
miR-21 Stool ND ND TaqMan quantitative
reverse transcription-PCR
Link et al., 2010
miR-106a
miR-221 Plasma ND ND Quantitative Reverse
Transcription-Polymerase
Chain Reaction
Pu et al., 2010
miR-144 Feces 74% 87% RT-qPCR Kalimutho et al.,
2011a
miR-21 Plasma 90% 90% Microfluidic Array
Technology
Kanaan et al., 2012
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
miR-18a,
miR-19a,
miR-19b,
miR-15b,
miR-29a, and
miR-335
Plasma ND Quantitative
reverse-transcription PCR
Giraldez et al., 2013
miR-532-3p,
miR-331,
miR-195, miR-17,
miR-142-3p,
miR-15b,
miR-532, and
miR-652
Plasma [area under curve (AUC)
= 0.868 (95% confidence
interval [CI]: 0.76–0.98)]
Microfluidic Array
Technology
Kanaan et al., 2013
miR-21, let-7g,
miR-31,
miR-92a,
miR-181b, and
miR-203
Serum Areas under ROC curve
were 0.900 and 0.923 for
the two sets of samples
Quantitative Reverse
Transcription Polymerase
Chain Reactions
Wang et al., 2014
miR-135b Plasma 78% for CRC, 73% for
advanced adenoma, and
65% for any adenoma
68% microRNA expression array Wu et al., 2014b
miR-18a Plasma ND ND Microfluidic Array
Technology
Komatsu et al., 2014
miR-92 Plasma 89% 70% Real-Time PCR Ng et al., 2009
miR-141 Plasma ND ND Quantitative Reverse
Transcription-Polymerase
Chain Reaction
Cheng et al., 2011
miR-601,
miR-760
Plasma 83% 69% qRT-PCR Wang et al., 2012
miR-18a,
miR-20a,
miR-21,
miR-29a,
miR-92a,
miR-106b,
miR-133a,
miR-143,
miR-145
Plasma ND ND TaqMan MicroRNA Array Luo et al., 2013
miR-378 Plasma ND ND Quantitative Real Time
PCR
Zanutto et al., 2014
miR-200c Plasma 84.60% 75.60% ND Zhang et al., 2013b
miR-18a
RNU2-1f
(Circulating U2
small nuclear
RNA)
Plasma 98% 91% qRT-PCR Baraniskin et al.,
2013
let-7a, miR-1229,
miR-1246,
miR-150,
miR-21,
miR-223, and
miR-23a
Serum ND ND Microarray analyses and
Real Time PCR
Ogata-Kawata et al.,
2014
(Continued)
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Table 1 | Continued
Anomalies Genetic marker Body fluid Sensitivity Specificity Method References
miR19a Plasma 80.95% for TNM I/II,
76.19% for TNM III/IV
79.25–
77.36%
Genome-wide miRNA
expression profiling assay
and qRT-PCR
Giraldez et al., 2013
miR19b
miR15b
miR-21 Serum 90% 90% Microfluidic array
technology
Kanaan et al., 2012
miR-29a Plasma 83% for CRC and 73%
for advanced adenomas
84.7%-
79.7%
Real Time PCR Huang et al., 2010
miR-92a
miR-21 Stool Higher expression ND Taqman-RT-PCR Link et al., 2010
miR-106a
miR-144 Stool 74% 87% RT-pre-amplification-qPCR Kalimutho et al.,
2011a
miR-221 Plasma 86% 41% Quantitative Reverse
Transcription-Polymerase
Chain Reaction without
RNA extraction
Pu et al., 2010
MicroRNA
Methylation
miR-34a Stool 77% 94% Methylation-Specific PCR Wu et al., 2014a
miR-34b/c 95% 100%
miR-34b/c Stool 75% ND Methylation-Specific PCR Kalimutho et al.,
2011b
miR-34b/c Stool ND ND ND Cho, 2011
miR-148a
is implicated in various malignancies, including lung adenocar-
cinoma, mucinous adenoma, ductal carcinoma of the pancreas,
and colorectal carcinoma (Kranenburg, 2005).
Bert Vogelstein et al. were able to detect Kras gene mutations
in patients with CRC, through hybridization and southern-blot
assays of the isolated CFNAs. Despite a small cohort (n = 9), suc-
cessful detection of a Kras mutation in eight of nine patients was
independent of tumor type being detected in both benign and
malignant neoplasms. The use of Kras mutation for detection did
not depend on the tumor localization as either distal or proximal
colonic tumors were detected (Sidransky et al., 1992).
This study stimulated further research to assess Kras mutation
in stool. In several research studies using small cohorts (<100),
it was an overall concordance between tissue and stool for Kras
genotype and it was possible to detect mutation even in 1000-
fold excess of wild-type Kras (Mixich et al., 2007). The overall
results showed that Kras mutations has 34–87.5% of sensitiv-
ity for detecting CRC patients and the specificity was very high,
reaching in some studies 100% (Dong et al., 2001; Doolittle et al.,
2001; Rengucci et al., 2001; Calistri et al., 2003; Chien et al., 2007;
Mixich et al., 2007; Zhang et al., 2011a).
In large asymptomatic cohort, Kras mutations were found
in the stool of 16.1% (5/31) of adenocarcinoma patients, 4.5%
(18/403) of advanced adenoma, 2.9% of patients with minor
polyps (49/648), and in 1.5% (22/1423) of subjects with negative
findings on colonoscopy (Imperiale et al., 2004).
APC
APC, an Adenomatous Polyposis Coli gene, encodes a tumor sup-
pressor protein that acts as an antagonist of the Wnt signaling
pathway, thus blocks epithelial cell proliferation. It is also involved
in other processes including cell migration and adhesion, apop-
tosis, spindle assembly, and chromosome segregation. Defects
in this gene cause FAP, an autosomal dominant pre-malignant
disease that usually progresses to malignancy. Disease-associated
mutations tend to be clustered in a small region designated the
mutation cluster region (MCR) and result in a truncated protein
product (Hanson and Miller, 2005).
APC mutations were analyzed in many studies. Except for the
study of Calistri et al. who found a very low frequency of APC
mutations with 2% detected in the stool samples (Calistri et al.,
2003), many researchers found APC mutations occurred in more
than 76% of the HNPCC patients and 54% of the sporadic CRC
(Koshiji et al., 2002; Traverso et al., 2002). APC mutations were
also detected in patients with minor polyps, but at low fraction
(2.5%) (Imperiale et al., 2004). The specificity of APC muta-
tions was found in more than 99% of the subjects with negative
findings on colonoscopy (Koshiji et al., 2002; Traverso et al.,
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2002). The combination of P53 anomalies with APC mutations
increased the sensitivity of cancer detection to 96.7% (Koshiji
et al., 2002).
The APC gene can carry relatively highly aberrant methylation
patterns on CpG islands. In DNA from tissue samples, Azuara
et al. (2010) showed the prevalence of promoter hypermethyla-
tion in tumor biopsies for APC in 20% (50/250) of the samples
tested. The analysis of 100 cases, paired normal mucosa yielded
zero percentage of APC methylation.
In DNA from stool samples, the authors detected APC methy-
lation in 37.5% (12/32) of patients with adenomas or carcinomas
and no methylation was found in the 22 non-neoplastic sub-
jects having either IBD or normal bowel (Azuara et al., 2010).
However, when Belshaw et al. evaluated APC gene methylation in
stool samples, they found no difference in methylation between
the CRC patients (n = 21) and the healthy volunteers (n = 12)
(Belshaw et al., 2004). The same conclusion resulted in the study
of Leung et al. in the serum. They analyzed APC methylation in
49 CRC patients and 41 age-matched controls as determined with
normal colonoscopy. There was no significant difference found
in the concentration of methylated serum DNA between can-
cer patients and controls for APC gene (p = 0.21) (Leung et al.,
2005).
TP53
The TP53 gene encodes a tumor suppressor protein contain-
ing transcriptional activation, DNA binding, and oligomeriza-
tion domains. TP53 responds to diverse cellular stresses to
properly regulate expression of target genes, thereby inducing
cell cycle arrest, apoptosis, senescence, DNA repair, or changes
in metabolism. In addition, P53 appears to induce apoptosis
through non-transcriptional cytoplasmic processes. Mutations in
this gene are associated with a variety of human cancers, including
hereditary cancers such as Li-Fraumeni syndrome (Toledo and
Wahl, 2006).
TP53 mutations were found in DNA stool samples of 25.8%
(8/31) of adenocarcinoma patients, 2.7% (11/403) of advanced
adenoma, 0.8% (5/648) of patients with minor polyps, and in
1.1% (16/1423) of subjects with negative findings on colonoscopy
(Imperiale et al., 2004). Higher detection rates were found in
the study of Khan et al. (2000) and Dong et al. (2001). In the
first study, they detected TP53 mutations in solid tumor samples
of 46% (19/41) colorectal carcinoma patients and in periph-
eral blood samples of 42% (8/19) patients (Khan et al., 2000).
In the study of Dong et al. the authors isolated DNA from
paired stools and primary tumor samples from CRC patients.
They detected TP53 mutations in the stools as well as in the
tumors of 59% (30/51) of the CRC patients (Dong et al.,
2001).
Poor performance of P53 mutations was seen in several stud-
ies. Calistri et al. (2003) analyzed TP53 exon 5–8 in the stool from
38 healthy individuals and paired stools and primary lesions from
56 CRC patients. While the detection sensitivity in the tissues was
34%, the sensitivity in the stools was less than 6% (Calistri et al.,
2003). Calistri et al. detected P53 mutations in the tumors of 37%
(17/46) of CRC patients and in the stool of only 6% (3/46) of the
CRC cases (Rengucci et al., 2001).
The combination of P53 mutations with other markers
increases the performance of the test to detect CRC patients.
Koshiji et al. evaluated both the TP53 and APC mutations in the
stool of 30 patients with sporadic CRC and 15 individuals with-
out cancer. The combination of TP53 and APC detected the CRC
patients with 97% of sensitivity and 100% of specificity (Koshiji
et al., 2002).
MMR GENES
Mismatch repair genes play a key role inmaintaining genomic sta-
bility, through participating in the mismatch repair pathway. The
major eukaryotic MMR genes are MLH1, MLH3, MSH2, MSH3,
PMS2, and MSH6 (from KEGG source record: ko03430). These
genes contain microsatellites coding repeats (Fishel et al., 1993;
Desai et al., 2000; Hansen et al., 2014). The deletion or inser-
tion of one or two nucleotides in these repeats causes a frameshift
mutation resulting in the production of a truncated and inac-
tive protein that ultimately affects the MMR biological pathway
(Iacopetta et al., 2010). Several other non-MMR genes were found
to contain microsatellites repeats and exhibit repeats instability
in CRC.
In many research studies, microsatellite instability was a rare
event. Calistri et al. evaluated microsatellite instability using a set
of fivemicrosatellite markers (D2S123, D5S346, D17S250, BAT25,
and BAT26) in 46 cases of CRC and 18 healthy individuals. In the
healthy individuals, no genetic alterations in stool were detected.
The diagnostic sensitivity of combining five microsatellites mark-
ers was 7% in stool-DNA (Rengucci et al., 2001). Imperiale
et al. used Bat-26 as microsatellite-instability marker. They found
Bat-26 deletions in the stool of 6.5% (2/31) of adenocarcinoma
patients, 1.2% (5/403) of advanced adenoma, 0.6% (4/648) of
patients with minor polyps, and in 1.1% (16/1423) of subjects
with negative findings on colonoscopy (Imperiale et al., 2004).
Albeit the low frequency of microsatellites instability, it is impor-
tant to combine microsatellites with others markers such as P53
and Kras mutations, because microsatellites instability could be
present in tumors lacking P53 and Kras mutations.
METHYLATION BIOMARKERS
DNAmethylation is an epigenetic mechanism that occurs in gene
promoter CpG sites, it is a well-known mechanism for tran-
scriptional silencing. Methylation instability events are frequently
observed in CRC, resulting in the inactivation of several tumor
suppressor genes or the activation of some tumor-related genes.
Thereby, methylation aberration quantification can be used in
diagnostics and prognosis of CRC.
Methylation in the stool. Muller et al. were the first to detect
the methylation anomalies in stool DNA of CRC patients using
secreted frizzled-related protein gene 2 (SFRP2). SFRP2 is a mem-
ber of the SFRP family that contains a cysteine-rich domain
homologous to the putative Wnt-binding site of Frizzled pro-
teins and acts as soluble modulators of Wnt signaling pathway.
As shown by many studies, the methylation of this gene is a
potential marker for the presence of CRC. In the study of Muller
et al., the methylation of SFRP2 was assessed in two indepen-
dent sets of patients (n = 23 and n = 26). SFRP2 methylation
had a detection sensitivity of 90 and 77% in the training and test
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sets, respectively, and the specificity was found to be 77% (Muller
et al., 2004). Similar results were found in other studies, methy-
lated SFRP2 was found to occur in 87–94.2% of patients with
CRC, 52.4–61.8% with adenomas and in 37.5–42.3% with hyper-
plasic polyps (Huang et al., 2007; Wang and Tang, 2008). In these
studies only 5–7% revealed methylated DNA out the normal indi-
viduals tested (Huang et al., 2007;Wang and Tang, 2008). Another
SFRP family member, secreted frizzled-related protein gene 1
(SFRP1) was detected methylated in the stool of CRC patients.
SFRP1 methylation was found to be statistically highly significant
between patients with colorectal neoplasia and the healthy group,
a sensitivity of 89% and specificity of 86% for the detection of
colorectal neoplasia was found for this gene (Zhang et al., 2007).
Themethylation in the stool of several others markers was pro-
posed as potential marker for CRC screening as single marker,
TFPI2 with sensitivity of 68% and specificity of 100% in the
cohort of 80 patients and 30 healthy controls (Zhang et al.,
2012), P16 with specificity of 20% and a specificity of 100%
(Abbaszadegan et al., 2007), Fibrillin-1 with sensitivity of 72%
and specificity of 93% (Guo et al., 2013), TFPI2 with sensitiv-
ity of 76% to 89% and a specificity of 79–93% (Glockner et al.,
2009), NDRG4 in the training set yielded a sensitivity of 61%, and
a specificity of 93% and in an independent test set of patients the
methylation of this gene yielded a sensitivity of 53% and a speci-
ficity of 100% (Melotte et al., 2009), the paraplegia-20 was found
with a sensitivity and specificity of 80.2 and 100%, respectively
(Zhang et al., 2013a).
To increase the sensitivity for calling true positives CRC
patients, researchers tried several combinations of methylation
markers. In 296 fecal samples, the combination of RASSF2 and
SFRP2 methylation detected 75% of patients with CRC, and 44%
of patients with advanced colorectal adenomas. Only 11% of the
subjects without neoplastic or active diseases were positives for
at least one marker (Nagasaka et al., 2009). RARB2, p16INK4a,
and MGMT methylation were combined to APC methylation.
The methylation of at least one marker was detected in the stools
of 75% (9/12) and 61.5% (16/26) of patients with carcinomas
and 60% (12/20) and 40% (8/20) of patients with adenomas in
the initial set and second set, respectively. The specificity of the
combined markers on healthy subjects was 100% (Azuara et al.,
2010). The methylation of MGMT, hMLH1, and vimentin were
detected, respectively, in 51.7, 30.0, and 38.3% of CRC, and in
36.5, 11, and 15.4% of colorectal adenomas, in combination the
sensitivity were 75 and 59.6%. The specificity of the three com-
bined markers was 86.5% (Baek et al., 2009). The combination
of the vimentin methylation to the DNA test used by Imperiale
et al. (2004), improved the sensitivity of CRC detection to 80%,
however, the specificity was decreased (Itzkowitz et al., 2007). The
diagnostic sensitivity by combining the following three mark-
ers AGTR1, WNT2, and SLT2 was 78% (Carmona et al., 2013).
The methylation frequencies of MAL, CDKN2A, and MGMT
were respectively, 78.3, 52.5, and 55.1% in CRC, 58.3, 41.7 and
37.5% in colon adenomas, 26.3, 15.8 and 10.5% in hyperplastic
polyps, and 3.8, 0 and 3.8% in healthy controls. However, the
sensitivity of the combination those three markers was 92.8%
in CRC and 70.8% in adenomas, showing significantly higher
than FOBT examination (Kang et al., 2011). The combination
of vimentin, OMSR, and TFPI2 methylation on stool-DNA from
107 individuals detected 86.7% of CRC and 76.5%, the adenoma,
the specificity was 86.7% (Zhang et al., 2011b).
Methylation abnormalities were also reported in the serum
of CRC patients by many authors. Methylation abnormalities
of APC, hMLH1, and HLTF were detected in the bloodstream
of CRC patients. Overall, 57% of CRC patients had methyla-
tion in at least one marker and 95% of the normal subjects
were not carrying the methylation in these genes (Leung et al.,
2005). A developed assay, designed to simultaneously quantify
the methylation of ALX4, SEPT9, and TMEFF2, was applied to
182 peripheral blood samples from CRC patients. Methylation of
ALX4, SEPT9, and TMEFF2 as single marker occurred only in 48,
75, and 71% of the CRC patients, respectively. In combination,
the sensitivity of the combined markers were improved to 81%
and the specificity was 90% (He et al., 2010).
Methylation anomalieswere also detected in urine fromCRC
patients. In a recent work, we investigated WIF1, ALX4, and
vimentin methylation in either urine or serum samples of 247
patients (90 patients with neoplasia and 157 control subjects
normal colonoscopy or having small adenomas less than 1 cm).
Hypermethylation of Wif-1 had higher diagnostic sensitivity than
Alx4 or vimentin. WIF1 methylation was observed in 26.7 and
32.6% in CRC cases (p < 0.001) and in 1.3% of the control
patients (p < 0.001) in either urine or serum. Interestingly, the
combination of serum and urine raised the neoplasia detection
rate to 47.8% in CRC cases, compared to 2.5% in control patients
(Mansour and Sobhani, 2009; Amiot et al., 2014).
MicroRNA BIOMARKERS
MicroRNAs are small non-coding RNAs that function at post-
transcriptional level to regulate gene expression by binding the
3′-untranslated region (3′UTR) of the target transcript (Maqbool
and Hussain, 2014). MicroRNA can be aberrantly expressed or
methylated in tumors and can be found and quantified either in
stool or plasma. These microRNAs signatures could be a good
noninvasive tool for the CRC detection (Cho, 2011; Maqbool and
Hussain, 2014).
In the stool the screening of feces for 648 microRNAs showed
that 39% of all these microRNAs can be detected (Kalimutho
et al., 2011a). High expression levels of miR-21, miR-106a,
miR-221, miR-29, miR-92, miR-34a, miR-34b/c, miR148a, and
miR-144 expressions were found in the stool from patients with
CRCs compared with healthy individuals (Huang et al., 2010;
Link et al., 2010; Cho, 2011; Kalimutho et al., 2011a,b; Wu et al.,
2014a). Other microRNAs, such as miR-34a, miR-b/c, and miR-
148a were also assessed in DNA stool from CRC patients but for
their methylation (Cho, 2011; Kalimutho et al., 2011b; Wu et al.,
2014a). Researchers demonstrated that either the expression or
the methylation of some microRNAs in the stool can be used as
potential markers for CRC detection.
In the plasma, many microRNAs analyzed show variable per-
formance for discriminating CRC from normal. In 103 CRC
patients and 37 healthy normal controls, the plasma level of miR-
221 is shown as a potential biomarker for differentiating CRC
patients from controls. At a specific cutoff value of expression,
miR-221 has the sensitivity of 86% and specificity of 41% (Pu
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et al., 2010). In the study investigating 380 plasmatic microRNAs,
miR-21 was found to differentiate CRC patients from controls
with 90% of sensitivity and specificity (Kanaan et al., 2012). In the
analysis of 196 plasma samples from 123 patients newly diagnosed
with sporadic colorectal neoplasia, miR-18a, miR-19a, miR-19b,
miR-15b, miR-29a, and miR-335 were significantly up-regulated
in CRC patients (Giraldez et al., 2013). They differentiate patients
with CRC from controls with area under curve (AUC) values
ranging from 0.80 (95% confidence interval [CI], 0.71–0.89) to
0.70 (95% CI, 0.59–0.80). In this study the only marker for
advanced adenomas (AAs) was miR-18a that was significantly up-
regulated in AAs compared with controls; the AUC value was 0.64
(95% CI, 0.52–0.75) (Giraldez et al., 2013). The investigation of
380 plasmatic microRNAs, in a small cohort of patients, revealed
a panel of eight microRNAs (miR-532-3p, miR-331, miR-195,
miR-17, miR-142-3p, miR-15b, miR-532, and miR-652) that was
found to distinguish polyps from controls with high accuracy
[(AUC) = 0.868 (95% [CI]: 0.76–0.98)] (Kanaan et al., 2013).
In several others studies, others microRNA, were found also in
the plasma of CRC patients as promising markers, such as, let-7g,
miR-31, miR-181b, miR-203, miR-135b, RNU2-1f, let-7a, miR-
1229, miR-1246, miR-150, miR-223, andmiR-23a (Ng et al., 2009;
Huang et al., 2010; Pu et al., 2010; Cheng et al., 2011; Kalimutho
et al., 2011a; Kanaan et al., 2012, 2013; Wang et al., 2012, 2014;
Baraniskin et al., 2013; Giraldez et al., 2013; Luo et al., 2013;
Zhang et al., 2013b; Komatsu et al., 2014; Ogata-Kawata et al.,
2014; Wu et al., 2014b; Zanutto et al., 2014).
CFNA MARKERS TRANSLATION FROM RESEARCH TO
CLINICAL USE
The biomarkers described to this point promise to be an excel-
lent way of detecting CRC, in the average-risk population. This
population typically includes individuals who are more than 50
years old or are first-degree relatives of CRC-affected patients or
patients with inflammatory bowel disease (IBD) possibly hav-
ing previously undetectable mucosal alterations, a prior step to
detectable premalignant neoplastic lesions. We summarize in the
following the advantages of CFNA based CRC detection.
Genetic anomalies: (1) appear in a large fraction of sporadic
non-hereditary tumors, (2) they appear in early stage during gut
cells transition to tumors, (3) they are well defined and described,
(4) a large number of cells carrying these anomalies are shed
from the developing tumor and could be found in biological
effluents, in particular stool, serum, and urine, (5) the genetic
anomalies can be easily identified by simple, quick, and relatively
inexpensive molecular approaches.
These noninvasive molecular approaches (1) show high sen-
sitivity and specificity in tumor detection and staging, (2) a
higher performance than the FOBT or FIT results, and (3) can
be used both as prognostic factor to monitor the disease progres-
sion and therapy responsiveness, by expanding or refining the
biomarker panel as our tumor-biology knowledge increases and
evolves.
There are multiple screening approaches that were endorsed
by the American Cancer Society (ACS) including stool or serum
DNA testing, and several companies are currently developing
tests based on these approaches. Nevertheless, studies published
to date that focus on the biomarker validation in large and
long-term randomized trials are rare and implementation in
screening trials have not been seen. For such validation and
implementation, some technical challenges could be encountered,
a. The DNA present in biological effluents could be a limiting
factor for the less sensitive molecular tools as the quantity of
CFNA extracted varies; stool contains higher DNA quantity
compared to serum and urine. From stool we can reproducibly
get a few μg of DNA per 100mg of stool; however, human
DNA represents merely 0.01% of the total stool DNA. The
urine seems to carry the lowest quantity of DNA, typically only
a few ng per ml of urine.
b. The origin of circulating free DNA in body fluids is not yet well
established. While the cell-free DNA found in CRC patients
may come from highly proliferative neoplastic colonic cells,
a normal cell (colonic cells or immune cells) origin has also
been indicated. Normal cells have been also found to ubiq-
uitously release DNA fragments (Stroun et al., 2000; van der
Vaart and Pretorius, 2007). The presence of different non-
tumor DNA sources may obscure the tumor DNA and make
genetic biomarker detection difficult. Indeed, the quantity of
circulating tumor nucleic acids found in body fluids of cancer
patients may be very low and varies considerably.
In plasma, Leary et al. showed that tumor DNA of cancer
patients ranges from 1.4 to 47.9% of wild-type (Leary et al.,
2012). Mouliere et al. showed that the quantity of mutant
DNA in plasma can be found even higher than what were pre-
viously described showing a variation range from 0.13 to 68%
in samples from mutation-positives CRC patients (Mouliere
et al., 2013). This variation can be influenced by cancer stag-
ing, where advanced stages carry more cell free DNA than early
stages, as was shown by Bert Vogelstein et al. who quanti-
fied the tumoral DNA extracted from plasma of CRC patients
and reported that the means of mutated DNA found were
0.02, 0.04, 0.94, and 11.05% for adenomas, stage A, stage B,
and stage D, respectively. The lowest quantity of mutant frag-
ment that was seen is 0.001%. While the quantity of mutant
fragment appears to correlate positively with the staging, the
lowest quantity was not specific to any stage (Diehl et al.,
2005).
In stool, Sidransky et al. (1992) showed that the tumor
mutated DNA represent a low rate, 4–8% the wild-type DNA
of CRC patients. Thus, both in plasma and in stool, the
high sensitivity of the molecular approach is needed to detect
patients with presumably curable CRC.
c. The quality of extracted CFNA can vary considerably since
body fluids do not preserve cell-free nucleic acid integrity.
Stabilization of the body fluids just after the collection is
strongly recommended, especially for stool samples.
d. Some body fluids can carry some inhibitors, such as food
digestion products, bacterial contaminants, and nucleic acids
released from others cells, that can reduce the CRC detection
performance.
e. The cell free nucleic acids found in blood, urine, and stool
are in general fragmented DNA, less than 200 bp. Then, the
evaluation of the size of extracted CFNA and targeting shorter
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regions should be considered to attain high performance of
detection.
f. High-Throughput Sequencing is a good tool that enables
screening the whole CFNA. High diagnostic value could be
achieved by using pair-end libraries and deep sequencing cov-
erage. However, the sequencing cost is still too high to be
implemented in routine as screening approach.
CONCLUSION
Research studies have shown that many genetic markers were
promising for CRC screening and diagnosis. A long term-clinical
trial evaluating all these biomarkers in the same cohort and
comparing stool, serum and urine is needed to select the best
composite panel. In addition, the challenges encountered with
nucleic acids extracted from body fluids need to be overcome to
identify the standard protocol and the robust tool to implement
these biomarkers as standard test for CRC screening, diagnosis,
and prognosis.
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